Product Information
GAVILYTE-G SOLUTION is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $0.0046 per ML under NDC 43386009019. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jun 1, 2009. Its Orange Book therapeutic-equivalence code is AA.
Strength
236; 2.97; 6.74; 5.86; 22.74 g/274.31g; g/274.31g; g/274.31g; g/274.31g; g/274.31g
Manufacturer
Lupin Pharmaceuticals Inc.NDC
43386009019
Classification
Generic
Dosage Form
POWDER, FOR SOLUTION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUSApproval Type
Generic (ANDA)
FDA Application
ANDA090231FDA Approved
6/1/2009
TE Code
AA
On Market Since
6/1/2009
Pharmacological Classes
Price Statistics
The NADAC for GAVILYTE-G SOLUTION has been published 671 times since Nov 28, 2013, and over the history we have for it it has risen 60.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0046 per ML |
|---|---|
| All-time high | $0.0054 (Nov 16, 2022) |
| All-time low | $0.0026 (Apr 18, 2018) |
| 52-week high | $0.0046 |
| 52-week low | $0.0044 |
| Median price | $0.0030 |
| Average price | $0.0034 |
| Largest weekly change | +42.3% (Apr 20, 2022) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the polyethylene glycol-3350 and Electrolytes market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
polyethylene glycol-3350 and Electrolytes market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Osmotic Laxative class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GAVILYTE-G SOLUTION?
The current National Average Drug Acquisition Cost (NADAC) for GAVILYTE-G SOLUTION, manufactured by Lupin Pharmaceuticals Inc., is $0.0046 per ML (NDC 43386009019), effective Sep 30, 2026.
How has the price of GAVILYTE-G SOLUTION changed over time?
Over the history we have for it, the NADAC for GAVILYTE-G SOLUTION has risen 60.3%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for GAVILYTE-G SOLUTION?
Since Nov 28, 2013, the NADAC for GAVILYTE-G SOLUTION has ranged from a low of $0.0026 (Apr 18, 2018) to a high of $0.0054 (Nov 16, 2022), with a median of $0.0030 per ML.
Are there cheaper alternatives to GAVILYTE-G SOLUTION?
No other NADAC-published product currently shares the active ingredient and strength of GAVILYTE-G SOLUTION in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures GAVILYTE-G SOLUTION?
GAVILYTE-G SOLUTION (NDC 43386009019) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.